Scientists from Bristol Myers Squibb and Lund University have outlined how mechanistic modelling can enhance process development for recombinant adeno-associated virus (rAAV)-based therapies. The modelling allows researchers to rapid identify optimal processing conditions and balance purity and yield. It also supports process characterisation needed for commercial process control strategies and is described as a rapid, flexible method for studying challenging parameter spaces.

‘Cyber incident’ continues to disrupt computer networks at some Sudbury-area schools – CTV News
Several schools in the Sudbury area continue to face disruptions in their computer networks due to an ongoing cyber incident. This has caused challenges for